Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Relative of a patient with a common genetic disease: which screening (haemochromatosis, familial hypercholesterolaemia, polycystic kidney disease, Wilson's disease, haemoglobinopathies, cystic fibrosis)

Genetics · Prevention, screening, pregnancy · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In France, nearly 388 300 people had a molecular genetics test in 2017, index cases or relatives, including 45 298 tests for type 1 haemochromatosis [1].

HFE haemochromatosis (relative of a C282Y homozygote)

Laboratory tests (adult relative)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Familial hypercholesterolaemia (first-degree relative)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Autosomal dominant polycystic kidney disease (adult at risk)

Laboratory tests

Imaging

Detailed explanation and international comparison (in French): read it in English (machine translation)

Wilson's disease (siblings, parents, children over 3 years)

Laboratory tests (preferably coordinated by the reference centre)

24-hour urine collection

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sickle cell disease or thalassaemia in the family (parents, siblings)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Cystic fibrosis in the family (parents, siblings, partner)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (26)
  1. Agence de la biomédecine. Génétique postnatale 2017 : rapport d'activité annuel de génétique postnatale 2017 (bilan 2017, données des laboratoires).
  2. Arrêté du 27 mai 2013 définissant les règles de bonnes pratiques applicables à l'examen des caractéristiques génétiques d'une personne à des fins médicales, annexe (modifiée par l'arrêté du 29 décembre 2022), et Code de la santé publique, article R. 1131-5 (décret n° 2023-1426 du 30 décembre 2023).
  3. Haute Autorité de santé. Prise en charge de l'hémochromatose liée au gène HFE (hémochromatose de type 1). Consensus formalisé d'experts, synthèse des recommandations, juillet 2005.
  4. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 8000 (mutation C282Y du gène HFE1), 4040 à 4042 (mucoviscidose, étude familiale) et 1635 (épreuve de la sueur).
  5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502.
  6. Kane SF, Roberts C, Paulus R. Hereditary Hemochromatosis: Rapid Evidence Review. Am Fam Physician. 2021;104(3):263-270.
  7. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (Red Book), 10e édition : Genetics, genetic screening, recommandations du 28/06/2024.
  8. Gastroenterological Society of Australia (GESA). Clinical update for general practitioners and physicians: Haemochromatosis. Updated 2021.
  9. Wiegman A, Bourbon M, Freiberger T, Gidding SS, Greber-Platzer S, Groselj U, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. Eur Heart J. 2026;47(26):3324-.
  10. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90.
  11. National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management (CG71). Publiée en 2008, mise à jour le 4 octobre 2019.
  12. US Preventive Services Task Force. Lipid Disorders in Children and Adolescents: Screening. Final Recommendation Statement, July 18, 2023.
  13. Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(2S):S1-S239.
  14. Dudley J, et al. Renal Association (UK Kidney Association). Clinical Practice Guideline: Monitoring children and young people with, or at risk of developing, Autosomal Dominant Polycystic Kidney Disease (ADPKD). Version finale de novembre 2018 ; révision prévue en novembre 2023.
  15. Srivastava A, Patel N. Autosomal dominant polycystic kidney disease. Am Fam Physician. 2014;90(5):303-307.
  16. Centre de référence de la maladie de Wilson et autres maladies rares liées au cuivre. Protocole national de diagnostic et de soins (PNDS) : maladie de Wilson. 8 novembre 2021.
  17. Shribman S, Marjot T, Sharif A, et al. Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. Lancet Gastroenterol Hepatol. 2022;7(6):560-575.
  18. European Association for the Study of the Liver, European Reference Network on Hepatological Diseases. EASL-ERN Clinical Practice Guidelines on Wilson's disease. J Hepatol. 2025.
  19. Filière de santé maladies rares MCGRE. Protocole national de diagnostic et de soins (PNDS) : syndromes drépanocytaires majeurs de l'enfant et de l'adolescent. Mars 2024.
  20. NHS England (Office for Health Improvement and Disparities). Sickle cell and thalassaemia screening programme handbook : chapitre « Antenatal screening ». Mis à jour le 11 juillet 2025.
  21. Hoferer A, Alashkar F, Cario H, Corbacioglu S, le Coutre P, Distelmaier L, Hegemann I, Kager L, Lobitz S, Schmugge Liner M, Sillaber C, Wörmann B, Dickerhoff R. Sichelzellkrankheiten. Leitlinie Onkopedia (DGHO), octobre 2024.
  22. Centre de référence mucoviscidose. Protocole national de diagnostic et de soins (PNDS) : mucoviscidose. Octobre 2025.
  23. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793-1806.
  24. UK National Screening Committee. Cystic fibrosis (pregnancy) : recommandation, dernière revue d'août 2019.
  25. Haute Autorité de santé. Santé préconceptionnelle. Note de cadrage validée par le Collège le 11 juin 2025.
  26. National Institute for Health and Care Excellence. Cystic fibrosis: diagnosis and management (NG78). 25 octobre 2017.